← Leaderboards
Alexandra Margaret Lynn Binder
University Of California Los Angeles
$4,845,425
Attributed
$5,819,389
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,859,133 · 5
By mechanism
R37$3,091,560 · 1
U54$2,039,744 · 1
R01$1,947,928 · 1
K07$468,494 · 1
P20$311,407 · 1
Top collaborators
- Elizabeth Marjorie Cespedes Feliciano3 shared
- Youping Deng1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Cynthia Diana Johanna Kusters$494,240
- David W Walker$10,114,526
- Morgan Elyse Levine$3,503,614
- Judith E Carroll$5,079,156
- Mina S Sedrak$3,437,312
Others in their field
Other Emerging Leaders on “Dna Methylation”
- Sonia Minikel Vallabh · Broad Institute, Inc.$14,507,691
- Chongyuan Luo · University Of California Los Angeles$9,805,856
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Michael-Christopher Keogh · Epicypher, Inc.$8,161,366
- Carl Rhodes · University Of Washington$8,047,567
- Himisha Beltran · Dana-Farber Cancer Inst$7,515,798
Research focus
Dna MethylationMalignant NeoplasmsCohortPatternAgingChronologyMortalityWomanMalignant Breast NeoplasmEpigenetic ProcessAccelerationBiological AgingCancer SurvivorMorbidity - Disease RateCancer DiagnosisCancer TherapyClinical TrialsInsightFrailtyBloodHigh RiskFunctional DeclineDiagnosisIncidence
Grant awards (15)
Center for Genome Research$2,039,744
U54 · FY2025 · HG · contact PI
Long-Term Trajectories of Accelerated Biological Aging and Functional Decline Associated with Breast Cancer and its Treatment$667,754
R01 · FY2025 · CA
Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention$626,968
R37 · FY2025 · CA · contact PI
Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention$632,572
R37 · FY2024 · CA · contact PI
Long-Term Trajectories of Accelerated Biological Aging and Functional Decline Associated with Breast Cancer and its Treatment$623,178
R01 · FY2024 · CA
Long-Term Trajectories of Accelerated Biological Aging and Functional Decline Associated with Breast Cancer and its Treatment$656,996
R01 · FY2023 · CA
Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention$636,830
R37 · FY2023 · CA · contact PI
Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention$645,794
R37 · FY2022 · CA · contact PI
Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention$549,396
R37 · FY2021 · CA · contact PI
Epigenetic Programming of Cardimetabolic Health during Childhood$225,167
P20 · FY2021 · GM · contact PI
Epigenetic Age as a Marker of Reproductive Age and Modifier of Invasive Breast Cancer Risk Among Postmenopausal Women$145,657
K07 · FY2020 · CA · contact PI
Epigenetic Programming of Cardimetabolic Health during Childhood$86,240
P20 · FY2020 · GM · contact PI
Epigenetic Age as a Marker of Reproductive Age and Modifier of Invasive Breast Cancer Risk Among Postmenopausal Women$84,800
K07 · FY2019 · CA · contact PI
Epigenetic Age as a Marker of Reproductive Age and Modifier of Invasive Breast Cancer Risk Among Postmenopausal Women$79,491
K07 · FY2019 · CA · contact PI
Epigenetic Age as a Marker of Reproductive Age and Modifier of Invasive Breast Cancer Risk Among Postmenopausal Women$158,546
K07 · FY2018 · CA · contact PI